Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 10.02%4.64B | -15.67%4.05B | -25.08%17.29B | -30.40%4.1B | -30.20%4.17B | -29.37%4.22B | -8.39%4.8B | 35.77%23.08B | 20.66%5.89B | 30.96%5.98B |
Cost of revenue | 10.81%3.23B | -8.05%2.96B | -25.70%12.07B | -28.02%3.01B | -30.72%2.93B | -29.69%2.92B | -12.80%3.21B | 28.39%16.24B | 14.08%4.18B | 26.34%4.23B |
Gross profit | 8.24%1.41B | -31.08%1.1B | -23.61%5.22B | -36.22%1.09B | -28.93%1.24B | -28.63%1.3B | 2.05%1.59B | 57.22%6.84B | 40.46%1.71B | 43.68%1.75B |
Operating expense | 9.87%528.78M | 12.33%503.76M | -1.73%1.92B | -9.17%529.86M | -6.13%458.16M | -4.08%481.3M | 18.52%448.45M | 26.36%1.95B | 40.84%583.38M | 25.42%488.08M |
Operating profit | 7.29%878.26M | -48.13%592.13M | -32.35%3.3B | -50.23%560.67M | -37.77%783.71M | -37.97%818.58M | -3.23%1.14B | 74.22%4.89B | 40.27%1.13B | 52.27%1.26B |
Net non-operating interest income (expenses) | 65.28%-4.07M | 128.37%3.63M | 74.75%-18.92M | 54.33%-8.38M | 175.32%13.97M | 38.55%-11.72M | 32.57%-12.8M | -1.03%-74.95M | 3.08%-18.35M | 0.30%-18.55M |
Non-operating interest income | 74.12%14.26M | 213.27%22.41M | 944.24%60.1M | 505.36%11.41M | 1,842.17%33.35M | 623.59%8.19M | 599.90%7.15M | 118.24%5.76M | 45.82%1.88M | 216.21%1.72M |
Non-operating interest expense | -7.93%18.33M | -5.87%18.78M | -2.09%79.02M | -2.22%19.79M | -4.40%19.38M | -1.46%19.91M | -0.25%19.95M | 5.05%80.71M | 0.04%20.24M | 5.84%20.27M |
Net investment income | -113.06%-11.83M | 414.77%13.87M | 189.60%110.26M | 87.09%-16.41M | 68.49%33.37M | 2,201.69%90.6M | 123.56%2.7M | -241.70%-123.06M | -725.04%-127.11M | 101.05%19.81M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -94.01%3.67M | 288.01%21.74M | 536.77%87.86M | 63.92%17.5M | 2,913.49%3.55M | 3,060,050.00%61.2M | 72.80%5.6M | 255.32%13.8M | 156.47%10.68M | -101.83%-126K |
Less:Other special charges | 94.01%-3.67M | -288.01%-21.74M | -536.77%-87.86M | -63.92%-17.5M | -2,913.49%-3.55M | -3,060,050.00%-61.2M | -72.80%-5.6M | -255.32%-13.8M | -156.47%-10.68M | 101.83%126K |
Other non-operating income (expenses) | 25,127.27%8.26M | -79.49%437K | -8.34%7.33M | -211.85%-321K | 62.98%5.56M | -101.92%-33K | -17.66%2.13M | -52.09%8M | -79.94%287K | -7.46%3.41M |
Income before tax | -8.80%874.29M | -44.54%631.81M | -25.86%3.49B | -44.25%553.06M | -33.53%840.16M | -26.14%958.64M | -1.37%1.14B | 74.30%4.71B | 32.04%992.01M | 52.48%1.26B |
Income tax | -3.45%279.43M | -44.92%192.29M | -26.80%1.06B | -42.33%171.86M | -36.38%248.96M | -26.11%289.41M | -4.68%349.11M | 85.16%1.45B | 39.78%298.03M | 60.97%391.3M |
Net income | -11.11%594.86M | -44.37%439.52M | -25.44%2.43B | -45.07%381.2M | -32.25%591.2M | -26.15%669.22M | 0.16%790.12M | 69.88%3.26B | 28.98%693.98M | 48.96%872.6M |
Net income continuous operations | -11.11%594.86M | -44.37%439.52M | -25.44%2.43B | -45.07%381.2M | -32.25%591.2M | -26.15%669.22M | 0.16%790.12M | 69.88%3.26B | 28.98%693.98M | 48.96%872.6M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -11.11%594.86M | -44.37%439.52M | -25.44%2.43B | -45.07%381.2M | -32.25%591.2M | -26.15%669.22M | 0.16%790.12M | 69.88%3.26B | 28.98%693.98M | 48.96%872.6M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -11.11%594.86M | -44.37%439.52M | -25.44%2.43B | -45.07%381.2M | -32.25%591.2M | -26.15%669.22M | 0.16%790.12M | 69.88%3.26B | 28.98%693.98M | 48.96%872.6M |
Gross dividend payment | ||||||||||
Basic earnings per share | -11.11%42.9 | -44.37%31.69 | -25.45%175.35 | -45.07%27.49 | -32.25%42.63 | -26.15%48.26 | 0.16%56.97 | 69.88%235.2 | 28.99%50.05 | 48.96%62.92 |
Diluted earnings per share | -11.11%42.8951 | -44.37%31.69 | -25.45%175.35 | -45.07%27.488 | -32.25%42.63 | -26.15%48.2571 | 0.16%56.97 | 69.88%235.2 | 28.98%50.0423 | 48.96%62.92 |
Dividend per share | 20.00%30 | 0 | 42.86%50 | 42.86%25 | 0 | 42.86%25 | 0 | 16.67%35 | 16.67%17.5 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |